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--- * Corresponding authors. Tel.: +34 922 318587; e-mail: adaranas@ull.es, jjfercas@ull.es, paivi.tammela@helsinki.fi † These authors contributed equally to the work Crown ethers, first described by Pedersen et al. 1 are macrocyclic polyethers well known for their noncovalent ion binding properties. Their common names include the number and type of atoms in the polyether ring. The ring size of these molecules controls their binding selectivity for a range of metal ions, thus 18-crown-6 has high affinity for potassium while 15crown-5 selects sodium cations. To explain this, a high complex stability has been associated with greater penetration of the metal cation into the polyether cavity.
Crown ether macrocycles are known in all ring sizes from 9 to at least 60, leading to great variety in structures (exceeding 10000 examples). 2 Therefore, crown ethers have been extensively studied from different aspects, including sensor applications, biological model systems (for example, abiotic ion channels) 3 and biological functionality, especially for anticancer and antimicrobial effects. 2, 4, 5 Crown ether derivatives function similarly to natural ionophores (such as gramicidin) and have thus been used to study several biological processes, in particular due to their channel forming and ion transport capabilities through lipid membranes. 5 Despite, large macrocylic compounds do not comply with the druglike, "rule-of-five" properties, 6 the potential of macrocycles for drug discovery has attracted considerable attention in the recent years. 7 
A R T I C L E I N F O A B S T R A C T
a Values are given in µM and are means of two to three experiments; standard deviation is given in parentheses.
b cLogP values were calculated using the Schrodinger small-molecule drug discover suite conditions.
Herein we report the synthesis of a series of crown ether acyl derivatives and the evaluation of their antimicrobial and antiproliferative properties. The antimicrobial activity was tested against Gram (+) and Gram (-) bacteria as well as against the model yeast Candida albicans. Previous reports describe dialkyldiaza-18-crown-6 ethers as inhibitors of bacterial growth. 8, 9 In addition, the antiproliferative profile was evaluated in vitro against a panel of human solid tumour cell lines. Thus we first synthetized compounds 1c, 2c and 3c where the same cyclohexyl side-chain was attached to 18-6, 15-5 and 12-4 crown ether moieties. Based on their antiproliferative activity (Table 1) we selected 18-crown-6 derivatives for further development, changing the length of the side chain and the size of the attached cyclic moiety. The general synthetic approach used included two alternatives: first the "Steglich esterification" using the acid of the selected side chain and a crown ether alcohol, utilizing dicyclohexylcarbodiimide as coupling agent and 4dimethylaminopyridine as catalytic base. 10 The second approach consisted in the usage of the corresponding acyl chloride as described in the supporting information. Using this simple strategy we obtained the corresponding derivatives 1a-q with yields ranging 60-95% (Fig. 1) .
The in vitro antiproliferative activity of the crown ether acyl derivatives was determined in HBL-100, HeLa, SW1573 and WiDr human solid tumor cells. Table 1 shows the results (expressed as GI 50 ) using the SRB assay. 11 The standard anticancer drugs cisplatin (CDDP) and etoposide (VP-16) were used as positive controls. The most active compound of the series was 1p and exhibited GI 50 values against all cells in the range 3.7-5.6 µM. When compared to CDDP and VP-16, compound 1p showed an improved biological activity in the resistant cell line WiDr. In addition, the non-tumor cell line BJ-hTert (telomeraseimmortalized human foreskin fibroblasts) was used to study the effect on a subset of the most potent crown ether acyl derivatives of the series. The results show that compounds 1k and 1m are inactive (GI50 > 100 µM), thus indicating some selectivity, whilst the other derivatives showed no discrimination between tumor and non-tumor cell lines. Further experiments will be necessary to explain this outcome.
Furthermore, the antimicrobial activity of the compounds was evaluated against a set of strains typically used in clinical antimicrobial testing by using the broth microdilution method according EUCAST and CLSI guidelines. 12, 13 All samples were initially tested at 50 µM. As can be seen from the primary screening results in Table 2 , compounds 1g and 1o were highly active against C. albicans ATCC 90028 and compounds 1l, 1o and 1p displayed significant activity against Staphylococcus aureus ATCC 25923, fully inhibiting the growth of this Grampositive bacterium. Confirmatory dose-response experiments were carried out for these compounds.
Compounds 1l, 1o and 1p showed MIC 90 values of 25 µM, 8.3 µM and 50 µM, respectively, against S. aureus (Table 3 ). Against C. albicans 1g and 1o exhibited MIC 90 values of 36 and 42 µM, respectively. All the compounds were inactive against the Gramnegative E. coli, possibly due to its outer membrane structure. Antimicrobial properties of crown ether derivatives have previously been studied by Leevy et al. 4 who demonstrated that activity against Escherichia coli is altered by the spacer length. Furthermore, Gram-positive Bacillus subtilis has been demonstrated to be in general more susceptible to different crown ether derivatives than E. coli. 4, 14 Interestingly, the activity of compound 1p, the most active compound in the antiproliferative experiments, was about 4-fold lower against S. aureus based on comparison between the GI 50 and MIC 50 values (Table 1, Table  3 ). On the other hand, compound 1o with MIC 50 of 7.2 µM against S. aureus was only moderately active against the cancer cells (GI 50 values in the range of 17-21 µM, Table 1 ). The structure-activity relationship (SAR) study clearly demonstrated that the size of the crown ether and the acyl side chain influence the bioactivity. Initially, it was established that the preferred crown ether was [18]-crown-6. The selection was based on the GI 50 values obtained for derivatives 1c, 2c and 3c in the antiproliferative profiling (Table 1) . Then, further efforts were devoted to study the influence of the acyl side chain on the antiproliferative activity. A clear trend could not be inferred from the biological data. For instance, a larger aliphatic linker improves the antiproliferative activity of 1g when compared to 1f. The side-chain length affects significantly the hydrophobicity of the compound, and thus calculated logP values for 1f and 1g are markedly different (1.46 and 4.63, respectively, Table 1 ). According to Supek et al., 14 logP of the molecule is the most important molecular descriptor in determining the biological activity of 18-crown-6 ethers, and not generally affected by features such as the side chain length or molecular symmetry. For our compounds, the calculated logP values vary from -0.96 to 4.63 (Table 1 ). The most active compounds have logP values >3, but some of the moderately active or inactive compounds have similar values, and thus the logP does not seem to be clearly correlated with biological activity according to our data. Based on our results, improved activity was obtained when the aromatic structure was close to the acyl group, as exemplified with compounds 1l, 1p and 1q. Further experiments are necessary to discern if the observed differences correlate to diverse mechanisms of action.
In conclusion, in this study we described an efficient strategy for synthesizing a series of crown ether acyl derivatives. Of the crown ether moieties 18-6, 15-5 and 12-4, 18-crown-6 ether core structure showed initially the best potential based on antiproliferation assays on human cancer cell lines and was thus chosen for synthesising a series of acyl derivatives. Compounds were evaluated for antiproliferative activity against HBL-100, HeLa, SW1573 and WiDr human solid tumor cell lines, and the most active compound 1p displayed GI 50 values in the range of 3.7-5.6 µM. Antimicrobial evaluation yielded compounds active against S. aureus and C. albicans; most active was compound 1o against S. aureus with MIC 90 value of 8.3 µM. These results will be helpful in understanding the biological effects of crown ether derivatives, and may thus aid the development of novel anticancer and antimicrobial agents based on crown ether moieties.
